Freidkin Lev, Landes Uri, Schamroth Pravda Nili, Aravot Dan, Kornowski Ran, Iakobishvili Zaza, Mager Aviv
Department of Cardiology, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv Israel.
Isr Med Assoc J. 2020 Feb;22(2):79-82.
Post-pericardiotomy syndrome (PPS) is a major cause of pericarditis, yet data on the risk of recurrence are limited, and the impact of steroids and colchicine in this context is unknown.
To examine the effect of prednisone and colchicine on the rate of recurrence of PPS.
Medical files of patients diagnosed with PPS were reviewed to extract demographic, echocardiographic, X-ray imaging, and follow-up data.
The study comprised 132 patients (57% men), aged 27-86 years. Medical treatment included prednisone in 80 patients, non-steroidal anti-inflammatory agents in 41 patients, colchicine monotherapy in 2 patients, and no anti-inflammatory therapy in 9 patients. Fifty-nine patients were given colchicine for prevention of recurrence. The patients were followed for 5-110 months (median 64 months). Recurrent episodes occurred in 15 patients (11.4%), 10 patients had a single episode, 4 patients had two episodes, and one patient had three episodes. The rate of recurrence was lower in patients receiving colchicine compared to patients who did not (8.5% vs. 13.7%), and in patients not receiving vs. receiving prednisone (7.7% vs. 13.8%) but the differences were non-significant. Twenty-three patients died and there were no recurrence-related deaths.
The rate of recurrence after PPS is low and multiple recurrences are rare. The survival of patients with recurrent PPS is excellent. Prednisone pre-treatment was associated with a numerically higher rate of recurrence and colchicine treatment with a numerically lower rate, but the differences were non-significant.
心包切开术后综合征(PPS)是心包炎的主要病因,但关于复发风险的数据有限,且在此情况下类固醇和秋水仙碱的影响尚不清楚。
研究泼尼松和秋水仙碱对PPS复发率的影响。
回顾诊断为PPS患者的病历,提取人口统计学、超声心动图、X线成像和随访数据。
该研究包括132例患者(57%为男性),年龄27 - 86岁。药物治疗包括80例患者使用泼尼松,41例患者使用非甾体抗炎药,2例患者使用秋水仙碱单药治疗,9例患者未接受抗炎治疗。59例患者接受秋水仙碱预防复发。患者随访5 - 110个月(中位64个月)。15例患者(11.4%)出现复发,10例患者复发1次,4例患者复发2次,1例患者复发3次。接受秋水仙碱治疗的患者复发率低于未接受秋水仙碱治疗的患者(8.5%对13.7%),未接受泼尼松治疗的患者复发率低于接受泼尼松治疗的患者(7.7%对13.8%),但差异无统计学意义。23例患者死亡,无复发相关死亡。
PPS后的复发率较低,多次复发罕见。复发PPS患者的生存率良好。泼尼松预处理与复发率在数值上较高相关,秋水仙碱治疗与复发率在数值上较低相关,但差异无统计学意义。